Impact of liraglutide on contrast-induced nephropathy and prognosis in elderly patients with type 2 diabetes after PCI
Liu Xiaogang
Fu Naikuan
Shao Dujing
Zhang Peng
Zhang Hong
Abstract：Objective To investigate the impact of liraglutide on contrast-induced nephropathy(CIN)and prognosis in elderly patients with type 2 diabetes(T2DM)after PCI.Methods A ret-rospective trial was conducted on 364 elderly T2DM patients undergoing PCI in Department of Cardiology of Tianjin Chest Hospital from January 2021 to June 2022.According to whether lira-glutide was used in the past,they were divided into liraglutide group(n=145)and control group(n=219).Their general clinical data were collected in the two groups.Propensity score matching was used to adjust confounding factors and to assign the patients.After propensity score matc-hing,there were 220 patients finally included,with 110 in each group.The levels of serum creati-nine(Scr),blood urea nitrogen(BUN),neutrophil gelatinase-associated lipocalin(NGAL),hyper-sensitive C-reactive protein(hs-CRP),malondialdehyde(MDA),superoxide dismutase(SOD),Bax/BCL-2 and Caspase 9,and incidence of CIN were compared before and in 48 h after PCI be-tween the matched patients from the two groups.These patients were followed up for 18 months after discharge.Multivariate logistic regression analysis was employed to determine the effect of liraglutide on the occurrence of CIN.Kaplan-Meier curve analysis and Log rank test were applied to compare the differences in the incidence of major adverse cardiovascular events(MACE)be-tween 2 groups.Results The levels of Scr,BUN,NGAL,hs-CRP,and MDA were significantly lower,and SOD level was obviously higher in the liraglutide group than the control group in 48 h after PCI(P＜0.05,P＜0.01).The liraglutide group had notably lower incidence of CIN than the control group within 48 h after PCI(7.27％vs 16.36％,P＜0.05).Multivariate logistic regression analysis indicated liraglutide as an independent protective factor against CIN(OR=0.341,95％CI:0.128-0.906,P=0.031).During the median follow-up period of 14.75(12.60,16.33)months,a lower MACE occurrence rate was seen in the liraglutide group than the control group(log rank x2=5.656,P=0.017).Conclusion Liraglutide can reduce the incidences of CIN and MACE in elderly T2DM patients after PCI,which may be associated with its anti-inflammatory and antioxidant effects.
Keywords：liraglutidediabetes mellitustype2percutaneous coronary interventioncontrast medianephrosisprognosis
Publication Date：2024-07-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 759-763 )